Compare Summit Therapeutics Inc (SMMT) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Western Union Co — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while Western Union Co trades at $7.14 (market cap $2.20B). The key difference: Summit Therapeutics Inc is far larger — about 5.5× Western Union Co's market cap, and Western Union Co pays a 13.33% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | WU | |
|---|---|---|
Market Cap | $12.06B | $2.20B |
Sector | Health | Technology |
52-Week High | $26.98 | $10.28 |
52-Week Low | $12.55 | $6.36 |
Enterprise Value | $11.39B | $2.10B |
Dividend Yield | — | 13.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Western Union (WU) trades at $7.13, up 1.42% with bearish technical signals and mixed fundamentals. The stock shows attractive valuation metrics with P/E of 5.69 and P/S of 0.56, but faces revenue decline from $4.5B in 2022 to $4.05B in 2025. Recent Q2 2026 earnings missed estimates at $0.31 vs. $0.42 expected, continuing a trend of earnings underperformance despite strong profitability margins.
The outlook remains challenging with declining revenue trends and bearish analyst sentiment (57% Hold, 31% Sell). Key risks include competitive pressure in money transfer services and digital transition challenges. The consensus price target of $7.14 offers minimal upside potential from current levels, suggesting limited near-term growth prospects for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
